Teos announced in May it was winding down operations, following disappointing Phase II study results for its anti-TIGIT antibody.

The FDA had made the request Friday, which Sarepta initially rebuffed, following the death of a third patient treated with one of the firm's gene therapies.

The study will compare neladalkib to Genentech's ALK inhibitor Alecensa in patients who've had no prior systemic treatment.

Researchers explored changes in survival outcomes and financial strain for NSCLC patients during a time when new targeted therapies were hitting the market.

The FDA requested Sarepta voluntarily stop distributing Elevidys after the death of a third patient who received one of the firm's gene therapies.

Company touted Kisqali's "replacement power" as another blockbuster faces generic competition and expressed optimism about ...

The privately funded basket trial makes good on its aim to enroll underrepresented groups amid a DEI-hostile federal funding ...

The biotech will add a pivotal Phase III cohort to its ongoing Phase I/II trial evaluating ATSN-201 in X-linked retinoschisis ...

A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...

The Whitrod family launched Genetic Cures for Kids in the hopes of finding a treatment for their daughter with hereditary ...

A study published by Caris showed that certain tumor types had very low or no HER2 overexpression, which has implications for biomarker testing strategies.

In a final draft guidance, the committee recommended the treatment for HR-positive HER2-negative early breast cancer patients, regardless of lymph node involvement.